Administrative Core

行政核心

• 批准号: 10514318
• 负责人: SUMIT K CHANDA
• 金额: $ 678.15万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-16 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10514318
• 关键词: 2019-nCoV; Antiviral Agents; Basic Science; Clinical Trials; Collaborations; Communication; Contracts; Coronavirus; Decision Making; Development; Disputes; Foundations; Goals; Grant; HIV; HIV-1; Human Resources; Immune System Diseases; Immune response; Influenza; Infrastructure; Institution; Laboratories; Licensing; Manuscripts; Medicine; Mentors; Mission; Modeling; Monitor; Names; National Institute of Allergy and Infectious Disease; Outcome; Performance; Periodicity; Personnel Management; Pharmacologic Substance; Policies; Preparation; Program Development; Progress Reports; Publications; RNA Viruses; Reagent; Research; Research Personnel; Research Project Grants; Resolution; Resource Allocation; Resource Sharing; Resources; Sampling; Scientist; Services; Site Visit; System; Talents; Technology; Time; Travel; Vaccine Adjuvant; Viral Pathogenesis; Virus; Work; base; career; career development; data dissemination; data management; data sharing; data submission; drug candidate; drug discovery; experience; experimental study; industry partner; meetings; member; multidisciplinary; next generation; organizational structure; pandemic disease; pandemic preparedness; programs; research and development; respiratory; skills; symposium; synergism; technology development

SUMMARY The Administrative Core will coordinate the CAMPP AViDD Center by 1) establishing an organizational structure centered on an Executive Committee responsible for – along with Director, Deputy Directors, and Scientific Advisory Board (SAB) – monitoring overall program progress and making decisions on staffing plans, allocation of resources, core usage, and other policies; 2) coordinating regularly held conference calls between the Center’s research teams and organizing annual meetings between the PIs, selected key personnel, the SAB and NIAID, as well as annual reverse site visits at NIAID; 3) assisting the investigators of this consortium in reagent and data sharing, manuscript preparations, IND preparations, the timely public dissemination of data, and the submission of annual progress reports to NIAID; and 4) providing support to early career research scientists and established investigators in other fields to develop independent research skills in antiviral drug research and development by implementing Developmental Research Projects and Mentored Project Programs. The Core Director has significant expertise in the coordination of program projects and large-scale multi-institutional consortia. He served as Director of the HINT consortium, a program project consisting of over 13 PIs at 10 institutions focusing on systems-based analysis of immune responses to HIV (P01 AI090935), and as Deputy Director of additional multi-institutional consortia; Fluomics (U19 AI106754) and Fluomics: The Next Generation (U19 AI135972), which focus on the use of systems-level technologies to identify host determinants of viral pathogenesis, both for influenza and SARS-CoV-2. More recently, he was named the PD/PI on a multi-PD/PI NIAID Vaccine Adjuvant Discovery Program contract (75N93019C00046), the PD/PI on the multi-PD/PI NIAID Reversing Immune Dysfunction for HIV-1 Eradication Program (UM1 AI164561), and the PD of the DoD program Development and Advancement of Broad-Spectrum Respiratory Antivirals (DABRA) (W81XWH-20-1-0270). Core Deputy Director Dr. García-Sastre has been the PD of the two Fluomics programs as well as the DABRA program mentioned above and is thus very well suited to assist Dr. Chanda in successfully leading this multi- disciplinary program. Deputy Director García-Sastre will oversee the Mentored Project to be initiated in year 2, supported by his experience in organizing the highly successful Fluomics program for junior level investigators (EMBED). Deputy Director Dr. Arnab Chatterjee will take responsibility for oversight of the Developmental Research program and has substantial experience relevant to the development and advancement of specific antivirals and related basic science studies, having advanced multiple drug candidates to major technology development licensing deals with Bristol-Myers Squibb, AbbVie, and Gilead as well as clinical trials.

概括 行政核心将通过以下方式协调 CAMPP AViDD 中心： 1) 建立一个组织 以执行委员会为中心的结构，负责与主任、副主任一起， 和科学咨询委员会 (SAB) – 总体监测计划进展并做出决策 2）定期举行协调 中心研究团队之间的电话会议以及组织研究中心之间的年度会议 PI、选定的关键人员、SAB 和 NIAID，以及 NIAID 的年度反向现场访问 3)； 协助该联盟的研究人员进行试剂和数据共享、手稿准备、IND 准备工作、及时公开传播数据以及向以下机构提交年度进展报告 NIAID；4) 为早期职业研究科学家和知名研究人员提供支持 其他领域发展抗病毒药物研发的独立研究技能 实施发展研究项目和指导项目计划。 在协调计划项目和大规模多机构方面拥有丰富的专业知识 他担任 HINT 联盟的董事，该联盟是一个由超过 13 名 PI 组成的项目。 在 10 个专注于基于系统的 HIV 免疫反应分析的机构 (P01 AI090935)， 并担任其他多机构联盟 (U19 AI106754) 的副主任； Fluomics：下一代（U19 AI135972），专注于系统级技术的使用 确定流感和 SARS-CoV-2 病毒发病机制的宿主决定因素。 他被任命为多 PD/PI NIAID 疫苗佐剂发现计划合同的 PD/PI (75N93019C00046)，多 PD/PI NIAID 逆转 HIV-1 免疫功能障碍的 PD/PI 根除计划 (UM1 AI164561) 以及国防部计划开发和推进的 PD 广谱呼吸抗病毒药物 (DABRA) (W81XWH-20-1-0270) 核心副主任 Dr. García-Sastre 是两个 Fluomics 项目以及 DABRA 项目的 PD 如上所述，因此非常适合协助 Chanda 博士成功领导这一多学科 副主任加西亚-萨斯特雷 (García-Sastre) 将监督将于 2019 年启动的指导项目。 第二年，他在组织非常成功的初级荧光组学项目方面的经验提供了支持 级调查员 (EMBED) 副主任 Arnab Chatterjee 博士将负责监督。 发展研究计划的负责人，并拥有与发展相关的丰富经验 以及特定抗病毒药物和相关基础科学研究的进展，取得了多项进展 与百时美施贵宝、艾伯维、 和吉利德以及临床试验。